Open-label Phase II trial reports early motor milestones with risdiplam

From Johns Hopkins University School of Medicine, Charlotte J. Sumner, M.D., presents an editorial on a study by Richard S. Finkel and colleagues, who report an open-label, Phase II trial of the pre-messenger RNA splicing modifier risdiplam in presymptomatic spinal muscular atrophy…